Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease.

"Declarations Ethics approval and consent to participateThe study obtained informed consent from DKD patients at stage III prior to their participation in the research. The research protocol received approval from the Ethics Committee of the Children’s Hospital of Chongqing Medical University, with the assigned Approval No. (2022) Ethics Review (Research) No. 328. Consent for publicationWritten informed consents were obtained from the DKD patients for publication of the information contained within this article. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This study received support from several sources, including the Joint Medical Research Programs of Chongqing Science and Technology Bureau and Health Commission Foundation (2023GGXM001), the National Key R&D Program of China (2022YFC2705101) and the National Natural Science Foundation of China (No. 82170720 and 82200906)."